Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
RedHill Biopharma Ltd is a drug manufacturers-specialty & generic business based in the US. RedHill Biopharma shares (RDHL) are listed on the NASDAQ and all prices are listed in US Dollars. RedHill Biopharma employs 182 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$4.89|
|52-week range||$5.90 - $11.52|
|50-day moving average||$7.59|
|200-day moving average||$7.23|
|Wall St. target price||$19.94|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.31|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-10)||-39.48%|
|1 month (2021-08-18)||-28.61%|
|3 months (2021-06-18)||-29.84%|
|6 months (2021-03-19)||-34.97%|
|1 year (2020-09-18)||-53.69%|
|2 years (2019-09-18)||-35.91%|
|3 years (2018-09-18)||8|
|5 years (2016-09-16)||14.6297|
|Revenue TTM||$84.5 million|
|Gross profit TTM||$28.3 million|
|Return on assets TTM||-25.81%|
|Return on equity TTM||-295.96%|
|Market capitalisation||$377.5 million|
TTM: trailing 12 months
There are currently 1.8 million RedHill Biopharma shares held short by investors – that's known as RedHill Biopharma's "short interest". This figure is 8.7% down from 2.0 million last month.
There are a few different ways that this level of interest in shorting RedHill Biopharma shares can be evaluated.
RedHill Biopharma's "short interest ratio" (SIR) is the quantity of RedHill Biopharma shares currently shorted divided by the average quantity of RedHill Biopharma shares traded daily (recently around 293962.48012719). RedHill Biopharma's SIR currently stands at 6.29. In other words for every 100,000 RedHill Biopharma shares traded daily on the market, roughly 6290 shares are currently held short.
However RedHill Biopharma's short interest can also be evaluated against the total number of RedHill Biopharma shares, or, against the total number of tradable RedHill Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case RedHill Biopharma's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 RedHill Biopharma shares in existence, roughly 40 shares are currently held short) or 0.0593% of the tradable shares (for every 100,000 tradable RedHill Biopharma shares, roughly 59 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against RedHill Biopharma.
Find out more about how you can short RedHill Biopharma stock.
We're not expecting RedHill Biopharma to pay a dividend over the next 12 months.
Over the last 12 months, RedHill Biopharma's shares have ranged in value from as little as $5.9 up to $11.52. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while RedHill Biopharma's is 1.3975. This would suggest that RedHill Biopharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
RedHill Biopharma Ltd. , a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 1/2a study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and Phase 2a study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-106, an encapsulated formulation for bowel preparation, which has completed Phase 2a study. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel. .
Everything we know about the MiNK Therapeutics IPO, plus information on how to buy in.
Everything we know about the Wetouch Technology IPO, plus information on how to buy in.
Everything we know about the Life Time Group Holdings IPO, plus information on how to buy in.
Everything we know about the Slinger Bag IPO, plus information on how to buy in.
Everything we know about the NSTS Bancorp IPO, plus information on how to buy in.
Everything we know about the Volcon IPO, plus information on how to buy in.
Everything we know about the Thomas James Homes IPO, plus information on how to buy in.
Everything we know about the FGI Industries IPO, plus information on how to buy in.
Everything we know about the Zhong Yang Financial Group IPO, plus information on how to buy in.
Everything we know about the Exscientia Ltd IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.